Vasodilator therapy for XXXX .

@entity1 @entity3159 @entity712 @entity1854
Six @entity1 with severe @entity712 were treated with @entity1854 intravenously. Four of the six @entity1 showed salutary responses and were successfully weaned from the NP with marked resolution of symptoms. No adverse side effects were observed. These four @entity1 and one additional @entity1 (who did not receive NP) were treated with @entity3159 by mouth in addition to digoxin and diuretics daily. Two of these @entity1 are entirely symptom free, and additional @entity1 is moderately improved, and the fourth @entity1 has shown minimal symptomatic improvement. Despite the severity of their pretherapy symptoms, only one @entity1 has died while receiving oral vasodilator therapy. This preliminary study suggests that afterload reduction may be life-saving in @entity1 who are virtually moribund because of @entity712 . This improvement can be maintained with oral vasodilator therapy and continuation of classic anticongestive therapy. However, afterload reduction has no effect on the underlying disease. Confirmatory studies are essential before this experimental mode of therapy is accepted for routine use in @entity1 and @entity1 .
